Antimicrobial susceptibility patterns of respiratory Gram-negative bacterial isolates from COVID-19 patients in Switzerland

Marina Gysin[a], Claudio Tirso Acevedo[b*], Klara Haldimann[a]*, Elias Bodendoerfer[a], Frank Imkamp[a], Karl Bulut[a], Philipp Karl Buehler[c], Silvio Daniel Brugger[b], Katja Becker[a], Sven N. Hobbie[a**]*

[a] *Institute of Medical Microbiology, University of Zurich, Gloriastrasse 30, 8006 Zurich, Switzerland*

[b] *Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland*

[c] *Institute for Intensive Care Medicine, University Hospital Zurich and University of Zurich, Raemistrasse 100, 8091 Zurich, Switzerland*

**MG, CTA, and KH contributed equally to this study; **correspondence:* sven.hobbie@uzh.ch

Corresponding author

Dr. Sven Hobbie
University of Zurich
Institute of Medical Microbiology
Gloriastrasse 30
CH-8006 Zurich
Phone +41 44 634 22 84
E-mail: sven.hobbie@uzh.ch

Abstract

Background

Bacterial superinfections associated with COVID-19 are common in ventilated ICU patients and impact morbidity and lethality. However, the contribution of antimicrobial resistance to the manifestation of bacterial infections in these patients has yet to be elucidated.

Methods

We collected 70 Gram-negative bacterial strains, isolated from the lower respiratory tract of ventilated COVID-19 patients in Zurich, Switzerland between March and May 2020. Species identification was performed using MALDI-TOF; antibiotic susceptibility profiles were determined by EUCAST disk diffusion and CLSI broth microdilution assays. Selected *Pseudomonas aeruginosa* isolates were analyzed by whole-genome sequencing.

Results

P. aeruginosa (46%) and *Enterobacterales* (36%) comprised the two largest etiologic groups. Drug resistance in *P. aeruginosa* isolates was high for piperacillin/tazobactam (65.6%), cefepime (56.3%), ceftazidime (46.9%) and meropenem (50.0%). *Enterobacterales* isolates showed slightly lower levels of resistance to piperacillin/tazobactam (32%), ceftriaxone (32%), and ceftazidime (36%). All *P. aeruginosa* isolates and 92% of *Enterobacterales* isolates were susceptible to aminoglycosides, with apramycin found to provide best-in-class coverage. Genotypic analysis of consecutive *P. aeruginosa* isolates in one patient revealed a frameshift mutation in the transcriptional regulator *nalC* that coincided with a phenotypic shift in susceptibility to β-lactams and quinolones.

Conclusions

Considerable levels of antimicrobial resistance may have contributed to the manifestation of bacterial superinfections in ventilated COVID-19 patients, and may in some cases mandate consecutive adaptation of antibiotic therapy. High susceptibility to amikacin and apramycin suggests that aminoglycosides may remain an effective second-line treatment of ventilator-associated bacterial pneumonia, provided efficacious drug exposure in lungs can be achieved.

Keywords

COVID-19, superinfection, ventilator-associated bacterial pneumonia, antimicrobial resistance, aminoglycoside, apramycin

1. Introduction

The emergence of the coronavirus disease 2019 (COVID-19) has resulted in high rates of intensive care unit (ICU) admissions of critically ill patients suffering from acute respiratory distress syndrome (ARDS). Respiratory viral infections predispose patients to secondary bacterial infections which are associated with increased morbidity and case fatality rates [1,2]. Particularly, secondary bacterial infections acquired in the setting of ICU-treatment are also independently associated with higher risk of mortality when compared with community-acquired infections [3].

Secondary bacterial infections in COVID-19 patients, hereafter referred to as superinfections, have not been intensively investigated thus far. Yet, mainly small cohort studies have reported high superinfection rates in critically ill and/or deceased COVID-19 patients. For instance, a retrospective cohort study by Zhou *et al.* documented secondary infections in 50% of deceased COVID-19 patients and ventilator-associated pneumonia in a third of mechanically ventilated patients, despite the fact that 95% of patients received antibiotic treatment [4]. A study by Du *et al.* described secondary bacterial infections at a late stage of disease in 10 of 21 deceased patients with the etiological spectrum including *Klebsiella pneumoniae*, *Staphylococcus spp.*, *Acinetobacter baumannii* and *Escherichia coli* [5]. However, a comprehensive antimicrobial resistance (AMR) surveillance of bacterial superinfection in critically ill COVID-19 patients treated in the ICU has yet to be reported.

In recent years, the incidence of infections caused by gram-negative bacilli (GNB), especially multidrug-resistant (MDR) organisms, in highly susceptible ICU patients has increased [6,7]. Particularly infections caused by MDR GNB are associated with a substantial risk of morbidity and in-hospital mortality for the critically ill [3]. The increased exposure of patients to antimicrobials and the global surge in hospital and especially ICU admissions due to the COVID-19 pandemic are rising concerns on the long-term impact on AMR in the acute care setting [8–10]. During the beginning of the COVID-19 pandemic, uncertainty regarding the novel disease has resulted in high antibiotic use since empirical antibiotic treatment was commonly prescribed before or at the time of hospital admission. A meta-analysis by Rawson *et al.* revealed that 72% of hospitalized patients received antimicrobial therapy despite low initial evidence of community-acquired co-infections at that time [11]. Similarly, the ISARIC WHO Clinical Characterization Protocol reported preceding anti-infective treatment in 76.6% of hospitalized patients [12].

A detailed understanding of the epidemiology and AMR pattern of bacterial superinfections in critically ill COVID-19 patients is urgently needed for adequate treatment. Here we report the bacterial spectrum and the antimicrobial susceptibility patterns of respiratory GNB isolated from ventilated ICU patients during the first COVID-19 wave in Switzerland. In addition, we investigate changes in the antimicrobial resistance over time for a single *P. aeruginosa* infection under antibiotic therapy using whole-genome sequencing (WGS).

2. Material and methods

2.1 Study population

This study was conducted within the MicrobiotaCOVID cohort, a single-center, prospective observational study conducted at the University Hospital Zurich, Switzerland. The study was approved by the Local Ethics Committee of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 – 00646). All patients with confirmed SARS-CoV-2 infection admitted to the ICU requiring mechanical ventilation between March and May 2020 were included (*n* = 40). Informed consent of all patients was obtained. The study cohort during this time period has been described recently [13].

2.2 Sample collection

Longitudinal collection and analysis of respiratory samples, such as tracheobronchial secretions (TBS) and bronchoalveolar lavages (BAL), was performed at frequent intervals from each ventilated patient. Samples were initially processed at the diagnostic laboratory of the Institute of Medical Microbiology (IMM) in the course of routine diagnostics. Species identification was performed with MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) using the direct formic acid transfer method [14]. Repetitive detected isolates of the same species in the same patients were included to monitor changes in antimicrobial susceptibility over time.

2.3 Antimicrobial susceptibility testing (AST)

Bacterial isolates were inoculated onto Columbia sheep blood (COS) agar and were incubated for 24 hours prior to antimicrobial susceptibility testing. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) disk diffusion method (version 8.0, January 2020) [15] was applied to determine the isolate's antimicrobial susceptibility to piperacillin/tazobactam (TPZ36), amoxicillin/clavulanate (AMC30), ceftriaxone (CRO30), cefepime (FEP30), meropenem (MEM10), amikacin (AK30), tobramycin (TOB10), gentamicin (CN10), trimethoprim/sulfamethoxazole (SXT25) ceftazidime (CAZ10) and ciprofloxacin (CIP5). The antibiotic SirScan Disks were obtained from i2a Diagnostics, Montpellier, France. Interpretative criteria in the EUCAST guidelines 2020 [16] were applied to set clinical resistance breakpoints and translate inhibition zone diameters into either resistant (R) or non-resistant (susceptible, S and "susceptible, increased exposure" (intermediate), I) phenotypes. Interpretative criteria for *P. aeruginosa* resistance to GEN were derived from the EUCAST guidelines 2019 [17] instead, since they have been removed from the 2020 version. Interpretative criteria for *Burkholderia cenocepacia* resistance to MEM and SXT (Table S3) were derived from the Clinical and Laboratory Standards Institute (CLSI) guidelines 2020 [18].

Antimicrobial susceptibilities were further assessed by broth microdilution assays following the CLSI guidelines [18,19]. Interpretative criteria in the EUCAST guidelines 2020 were followed to set clinical breakpoints and translate MICs into drug susceptibility. Interpretative criteria for *P. aeruginosa* resistance to GEN were derived from the EUCAST guidelines 2019 instead, since they have been removed from the 2020 version. For the aminoglycoside plazomicin, the FDA-identified interpretative criteria of 2, 4, and ≥8 mg/L were used for susceptible, intermediate, and resistant, respectively (https://www.fda.gov/drugs/development-resources/plazomicin-injection as of 06/14/2019, date last accessed 12/16/2020).

135 The minimal inhibitory concentration (MIC) performance standard for the aminoglycoside apramycin
136 was set to a modal value of 4 mg/L for *E. coli* ATCC 25922 and an acceptable range of 2-8 mg/L.
137 Epidemiological cut-off values (ECOFFs) of 8 mg/L for *Enterobacterales* and 16 mg/L for *P. aeruginosa*
138 were used as interpretative criteria [20].

139 **2.4 Whole-Genome Sequencing of selected *P. aeruginosa* isolates**

140 Whole-genome sequencing was applied to detect resistance determinants of eight selected
141 consecutive *P. aeruginosa* isolates from a single patient.

142 DNA was extracted from cultures of the clinical isolates grown on Columbia sheep blood (COS) agar
143 plates using the DNeasy® UltraClean® Microbial kit (Qiagen, Hilden, Germany) according to the
144 manufacturer's recommendations. Library preparation was performed using the Qiagen® QIAseq FX
145 DNA kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. Sequencing library
146 quality and size distribution were analyzed on a fragment analyzer automated CE system (Advanced
147 Analytical Technologies Inc., Heidelberg, Germany), using the fragment analyzer 474 HS next
148 generation sequencing (NGS) kit. Sequencing libraries were pooled in equimolar concentrations and
149 paired-end sequenced (2 × 150 bp) on an Illumina MiSeq platform (Illumina®, San Diego, CA, USA).

150 Raw sequencing reads (FASTQ) were filtered and trimmed using Trimmomatic [21]. CONTIGS were
151 assembled from processed FASTQ files using SPAdes (v3.13.0). To identify antibiotic resistance
152 determinants CONTIGS were analyzed using the command line version of Resistance Gene Identifier
153 (RGI; v4.2.2) and CARD (Comprehensive Antibiotic Resistance Database, v3.1.0) [22,23].

154

155 **3. Results**

156 **3.1 Species distribution**

157 A total of 168 GNB were identified in 19 of the 40 patients (48%) of the MicrobiotaCOVID cohort. A
158 representative subset of 70 GNB, including repetitive isolates from 17 patients, were further analyzed
159 in this study.

160 The two largest groups of pathogens in our panel of COVID-19 GNB isolates were *Pseudomonas*
161 *aeruginosa* (46%) and *Enterobacterales* (36%). *Burkholderia cenocepacia* (17%) was found in smaller
162 numbers, as well as a single *Acinetobacter bereziniae* isolate (Figure 1A). Within the order of
163 *Enterobacterales*, *Enterobacter cloacae* (32%) and *Klebsiella pneumoniae* (28%) were the two
164 predominant species, followed by *Klebsiella aerogenes* (20%), *Citrobacter spp.* (16%), and
165 *Escherichia coli* (4%) (Figure 1B). The species distribution of the analyzed subset (*n* = 70) was shown
166 to be representative for all the identified Gram-negative isolates of the MicrobiotaCOVID cohort
167 (*n* = 168, Figure S1).

168



Figure 1. Subset distribution of all Gram-negative respiratory isolates studied (A) and further differentiation within the order of *Enterobacterales* (B).

169

170

171 **3.2 Antimicrobial susceptibility patterns**

172 The antimicrobial susceptibility profile of all *Enterobacterales* and *P. aeruginosa* isolates (*n* = 57) was
173 determined by the EUCAST disk diffusion method (Figure 2, Table S1).

174 A high proportion of *P. aeruginosa* isolates was found to be resistant to the standard-of-care
175 antibiotics cefepime (FEP, 56.3%), ceftazidime (CAZ, 46.9%), and meropenem (MEM, 50.0%).
176 *P. aeruginosa* resistance to piperacillin/tazobactam (TZP, 65.6%) was the highest for any of the
177 relevant drugs tested in this study. Resistance to ciprofloxacin (CIP) was comparatively low in
178 *P. aeruginosa* isolates (15.6%).

179 *Enterobacterales* isolates showed likewise resistance to TZP (32.0%), ceftriaxone (CRO, 32.0%), and
180 CAZ (36.0%). The high resistance of *Enterobacterales* to amoxicillin/clavulanate (AMC, 72.0%) was not
181 surprising considering intrinsic (chromosomal) AmpC resistance of *E. cloacae*, *K. aerogenes*, and
182 *C. freundii* [24]. The *Enterobacterales* resistance was lower for FEP (8.0%) and
183 trimethoprim/sulfamethoxazole (SXT, 4.0%).

184 Disk diffusion further revealed all the *P. aeruginosa* isolates to be susceptible to gentamicin (GEN),
185 tobramycin (TOB), and amikacin (AMI). Aminoglycoside susceptibility was also high for the
186 *Enterobacterales* isolates with only a single *E. coli* isolate lacking susceptibility to gentamicin and
187 tobramycin. This rendered aminoglycosides the most effective drug class *in-vitro* for the respiratory
188 clinical isolates studied here, and the only drug class with full coverage of all *P. aeruginosa* isolates.

189 To study the antimicrobial susceptibility profiles in more detail and to test additional antibiotics not
190 routinely included in the disk diffusion panel, the clinical isolates were also analyzed by broth
191 microdilution assays to determine the minimal inhibitory concentration (MIC) (Figure 3, Table S2). For
192 those drugs tested by both disk diffusion and broth microdilution, the results correlated well between
193 the two methodologies (Figure S2 and S3).

194 Broth microdilution assays confirmed the results of the disk diffusion assay with regards to high
195 aminoglycoside susceptibility of both *P. aeruginosa* and *Enterobacterales* and extended the
196 aminoglycoside panel by including plazomicin (PLZ) and apramycin (APR). Both PLZ and APR showed
197 full coverage of *Enterobacterales*. Apramycin additionally showed full coverage of *P. aeruginosa*
198 (Figure 3, Table S2).

199



200

Figure 2. Inhibition zone diameter distributions for respiratory *Enterobacterales* and *P. aeruginosa* isolates from ventilated COVID-19 patients. Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), ceftazidime (CAZ), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), tobramycin (TOB), amikacin (AMI), amoxicillin/clavulanate (AMC), ceftriaxone (CRO) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacterales* (orange) and *P. aeruginosa* (blue) isolates, respectively.

201

202



Figure 3. Minimal inhibitory concentration (MIC) distributions for respiratory *Enterobacterales* and *P. aeruginosa* isolates from ventilated COVID-19 patients. Vertical dashed lines indicate the EUCAST clinical resistant breakpoint values for piperacillin/tazobactam (TZP), cefepime (FEP), meropenem (MEM), gentamicin (GEN), tobramycin (TOB), amikacin (AMI) and trimethoprim/sulfamethoxazole (SXT) for *Enterobacterales* (orange) and *P. aeruginosa* (blue) isolates, respectively. In the case of plazomicin (PLZ), the vertical dashed line indicates the FDA-identified interpretative criteria. In the case of APR (apramycin), vertical dashed lines indicate the proposed ECOFF values [20].

203

204 **3.3 Antibiotic resistance development in *P. aeruginosa* under antimicrobial selection pressure**

205 Next, we analyzed bacterial isolates that were repetitively derived from individual patients to study
206 changes to antimicrobial susceptibility in response to antibiotic therapy. A decrease in antimicrobial
207 susceptibility over the course of treatment was particularly pronounced for *P. aeruginosa* (Figure S4).
208 This prompted us to select a single *P. aeruginosa* infection for the analysis of phenotypic and genotypic
209 changes in response to antibiotic therapy across eight consecutive isolates collected on day 9, 10, 16,
210 17, 18, 22, 29 and 37 (Figure 4).



Figure 4. Antibiotic resistance development of *P. aeruginosa* in a single patient during antibiotic therapy. (A) The disc diffusion inhibition zones for piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), ceftazidime (CAZ), cefepime (FEP), tobramycin (TOB) and gentamicin (GEN) are shown for eight consecutive isolates (labeled from 1-8), collected after 9, 10, 16, 17, 18, 22, 29 and 37 days of ICU admission. Horizontal dashed lines indicate the EUCAST clinical resistant breakpoint values for TZP, MEM, CIP, CAZ, FEP, TOB and GEN, according to color. The bracket describes the resistance determinant detected in the *P. aeruginosa* isolates by whole-genome sequencing. (B) Antibiotic therapy of the patient. Piperacillin/tazobactam (TZP), meropenem (MEM), ciprofloxacin (CIP), gentamicin (GEN), ceftazidime/avibactam (CZA) and tobramycin (TOB).

211

212 Initial isolation of *P. aeruginosa* from TBS of the patient studied here, occurred on day 4 after ICU
213 admission (Figure S4, ID 05). After seven days of antibiotic therapy with piperacillin/tazobactam (TZP)
214 resistance was not only detected against this broad-spectrum β-lactam antibiotic/β-lactamase
215 inhibitor combination, but also against third and fourth generation cephalosporins (CAZ and FEP)
216 (Figure 4). Consecutively, antibiotic therapy was switched to meropenem (MEM) and subsequent
217 isolates (isolates 2 and 3) yet again showed susceptibility to TZP and cephalosporins (CAZ and FEP).
218 After eight days of antibiotic therapy with MEM, repetitive isolates showed resistance to MEM
219 (isolates 4 to 8) and eventually to TZP as well as extended-spectrum cephalosporins (CAZ and FEP),
220 indicating a multidrug-resistant gram-negative (MDRGN) infection. After an antibiotic-free period,
221 therapy with ciprofloxacin (CIP) was initiated and continued for 9 days. Gentamicin was added after
222 resistance to fluoroquinolones including CIP occurred (Figure 4 and Figure S4, ID 05). Antibiotic
223 therapy was switched to ceftazidime/avibactam (CZA) for a total of 11 days with *P. aeruginosa* still
224 detectable throughout antibiotic treatment. Finally, therapy with inhaled tobramycin (TOB) was
225 started but stopped again after a total of 6 days, as *P. aeruginosa* was still detectable and the patient
226 showed no signs of acute infection, thus indicating colonization of the patient with MDR *P. aeruginosa*.

227 Finally, we performed whole-genome sequencing of the eight consecutive isolates in an attempt to
228 detect possible resistance determinants that may explain the phenotypic progression. Whole-genome
229 analysis indicated that all eight isolates originated from the same clone indeed. The clone was
230 characterized by two β-lactamases that commonly occur in *P. aeruginosa*: an OXA-50 like type and
231 PDC-91. A 1-bp deletion causing a frameshift in the gene encoding the transcriptional regulator NalC
232 of the *mexAB-oprM* multidrug efflux pump operon was found in isolates 4 till 8, but was absent in the
233 first three isolates, providing a rationale for the drop in susceptibility from day 17 onwards (Figure 4).

234

4. Discussion

The present study is one of the first microbiological studies to report a detailed antimicrobial susceptibility profiling of Gram-negative bacterial superinfections in ventilated COVID-19 patients. The sample size is limited and has a strong geographic bias, but some important conclusions can nevertheless be drawn and will add to a growing number of similar studies that we expect from other geographic locations.

The etiology found here for late-onset VABP in COVID-19 patients resembles the diversity of Gram-negative pathogens typically found in nosocomial pneumonia [25]. Previous cohort studies have reported diverse etiology in COVID-19 confirmed cohorts, with *A. baumannii*, *K. pneumoniae*, *E. coli* and *P. aeruginosa* as predominant infecting agents [26–28]. The species distribution and resistance pattern within individual studies may vary depending on the geographic and local ICU etiology of resistant isolates, study-specific patient recruitment and sample selection, and the treatment history of prior antibiotic exposure in regular VABP patients and COVID-19 patients.

Besides *P. aeruginosa* and *Enterobacterales*, *Burkholderia cenocepacia* were the third most common isolates encountered in this study. The latter is regarded a natural colonizer and an opportunistic pathogen in immune-compromised patients, with a naturally high intrinsic resistance to various antibiotics [29]. Trimethoprim-sulfamethoxazole (SXT) is used as a first-line option for the suppression/control of the infection. Since we only had a small number of *B. cenocepacia* isolates in our study, all of which were susceptible to SXT (Table S3), we decided to focus further analysis on only *P. aeruginosa* and *Enterobacterales*.

For the *Enterobacterales* isolates we found a relatively high level of resistance to TZP, CRO, CAZ, and AMC. This may be explained by prior selection related to early antibiotic treatment in the course of COVID-19 infection, since AMC, CRO, and TZP are commonly used in Switzerland as first-line drugs for nosocomial bacterial pneumonia. Some of the species within the order of *Enterobacterales* are further characterized by a chromosomally encoded AmpC β-lactamase, which also contributes to decreased susceptibility to selected β-lactam antibiotics and in particular AMC [24]. *Enterobacterales* resistance to FEP, SXT, MEM and aminoglycosides was low or absent in comparison to the aforementioned antibiotics. Only a single *E. coli* isolate (Figure 2 and 3 and Figure S2), showed resistance to gentamicin and tobramycin, without prior exposure to aminoglycosides in the patient's treatment regimen.

P. aeruginosa represents a notorious pathogen of nosocomial infections often characterized by MDR, especially in VABP and cystic fibrosis patients [30,31]. Treatment success is greatly hampered due to its intrinsic and adaptive resistance to nearly all available antipseudomonal agents. Important determinants driving resistance in *P. aeruginosa* are multidrug efflux pumps, alterations to its outer membrane porins, and the expression of β-lactamases [32]. For the *P. aeruginosa* isolates analyzed here, we found very high levels of drug resistance to TZP, FEP, CAZ and MEM.

Importantly, antibiotic resistance levels seemed to increase over the course of antibiotic treatment in the *P. aeruginosa* isolates (Figure 4 and Figure S4). Resistance to TZP but also to third- and fourth-generation cephalosporins (CAZ and FEP, respectively) occurred on day 7 of TZP therapy as reflected in isolate 1 (Figure 4). This may be attributable to the two β-lactamases (OXA-50 like type and PDC-91) which were identified by WGS in all eight isolates from that single infection. The OXA-50 like type enzyme is a class D β-lactamase, which has a reported narrow hydrolyzing spectrum including

276 piperacillin but not meropenem [33]. PDC-91 is an inducible AmpC-like β-lactamase conferring
277 resistance to broad-spectrum cephalosporins [34]. Surprisingly, we observed a completely susceptible
278 phenotype in isolates 2 and 3. We hypothesize that these two isolates were colonizing a different
279 niche in the airway tract, potentially with the formation of a biofilm, which could have limited
280 antibiotic exposure and resulted in a sensitive phenotype in the disc diffusion assay.

281 The MexAB-OprM efflux pump is a clinically relevant efflux system in *P. aeruginosa* [24,35].
282 Transcription of the corresponding genes is under regulation of MexR, NalC and NalD. Overexpression
283 of this efflux pump can be induced by mutations in *nalC*, leading to resistance against β-lactams
284 (except imipenem) and quinolones but not aminoglycosides [36].

285 WGS analysis identified a 1-bp deletion in the suppressor gene *nalC* of isolates 4 – 8, which likely
286 renders the corresponding protein non-functional and eventually results in over-expression of MexAB-
287 OprM. Notably, at the same time we observed a gradual to massive decrease in TZP, CAZ, FEP, CIP and
288 MEM susceptibility in the consecutive isolates (Figure 4), indicating the importance of the *nalC*
289 mutation in developing the MDR phenotype of isolate 8. However, imipenem has been described as
290 unaffected by the MexAB-OprM efflux pump [36]. Hence, the observed resistance to imipenem
291 (Figure S4, ID 05) may be caused by a different resistance mechanism. In addition, expression levels
292 of *mexAB-oprM* or of *oxa-485* and *pdc-91* have not been tested, therefore the precise correlation of
293 each drug susceptibility to its resistance mechanism remains to be investigated. Nevertheless, the
294 detected resistance determinants in combination with the antibiotic treatment history provide a
295 rational explanation for the emergence of this MDR *P. aeruginosa* strain.

296 In the case of pneumonia, a main determinant of antibiotic efficacy is the drug concentration in the
297 lung parenchyma tissue. Although intravenous aminoglycosides penetrate in lung parenchyma and
298 bronchial secretions, measured lung tissue concentrations have been found to be relatively low for
299 some aminoglycosides, because plasma concentrations are kept low in clinical care to avoid systemic
300 toxicity [37]. While therapy with inhaled aminoglycosides are well described and tolerated in the
301 treatment of cystic fibrosis, administration of nebulized aminoglycosides in acute pulmonary
302 infections has largely remained an off-label domain and requires further evaluation [38]. Our results
303 warrant further exploration of intravenous or inhaled aminoglycosides as a critical component in the
304 treatment of HAP/VAP with MDR GNB in COVID-19 patients. The drug candidate apramycin, currently
305 in clinical development, has previously been suggested to have best-in-class coverage of drug-resistant
306 GNB [20,39–41], which was confirmed for VAP bacterial isolates from COVID-19 superinfections here.

307 **5. Conclusion**

308 In conclusion, resistance to first-line antibiotics was prevalent in bacterial isolates from ventilated
309 COVID-19 patients in Switzerland during the first wave of COVID-19. It is conceivable that AMR plays
310 a key role in those ventilated patients that contract a VABP despite empiric treatment, and contributes
311 to morbidity and case fatality rates of patients that in addition to COVID-19 treatment are likely to
312 receive multi-drug regimens of second-line or last-resort antibiotics to control the bacterial infection.
313 Aminoglycosides have regained interest as potent broad-spectrum antibiotics in the face of β-lactam
314 and specifically carbapenem resistance, and represent a treatment option less toxic than polymyxins.
315 In the present study, the aminoglycosides drug class was the only one that was virtually not affected
316 by resistance.

317 **List of Abbreviations**

318 AMI	Amikacin
319 AMC	Amoxicillin/clavulanate
320 APR	Apramycin
321 AST	Antimicrobial Susceptibility Testing
322 CIP	Ciprofloxacin
323 CLSI	Clinical and Laboratory Standards Institute
324 CRO	Ceftriaxone
325 CST	Colistin
326 CAZ	Ceftazidime
327 CZA	Ceftazidime/avibactam
328 ECOFF	Epidemiological Cutoff
329 EUCAST	European Committee on Antimicrobial Susceptibility Testing
330 FEP	Cefepime
331 GEN	Gentamicin
332 GNB	Gram-negative bacilli
333 MEM	Meropenem
334 MIC	Minimal Inhibitory Concentration
335 PLZ	Plazomicin
336 SXT	Trimethoprim/sulfamethoxazole
337 TOB	Tobramycin
338 TZP	Piperacillin/tazobactam

339

340

341

342 ## Declarations

343 **Ethics approval and consent to participate:** The study was approved by the Local Ethics Committee
344 of the Canton of Zurich, Switzerland (Kantonale Ethikkommission Zurich BASEC ID 2020 – 00646). All
345 necessary patient/participant consent has been obtained and the appropriate institutional forms have
346 been archived.

347 **Consent for publication:** All necessary patient/participant consent has been obtained and the
348 appropriate institutional forms have been archived.

349 **Availability of data and material:** Data generated or analyzed during this study are included in this
350 published article and its supplementary information files. The genome sequencing files generated and
351 analyzed during the current study are available from the corresponding author on reasonable request.

352 **Competing interests:** Author SNH is a shareholder in Juvabis AG. All other authors declare no
353 competing interests.

354 **Funding:** This study was partially funded by Innosuisse (project no. 45893.1 INNO-LS). The work was
355 supported by the Clinical Research Priority Program of the University of Zurich for the CRPP Precision
356 medicine for bacterial infections; and by the University of Zurich, Institute of Medical Microbiology.
357 SDB is supported by a Fellowship from the Promedica Foundation (1449/M). The funders had no role
358 in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

359 **Authors' contributions:** All authors contributed to the study conception and design. Material
360 preparation, data collection and analysis were performed by Marina Gysin, Claudio Tirso Acevedo,
361 Klara Haldimann, Elias Bodendoerfer, Frank Imkamp, Karl Bulut, Katja Becker, and Sven N. Hobbie. The
362 first draft of the manuscript was written by Marina Gysin and all authors commented on previous
363 versions of the manuscript. All authors read and approved the final manuscript.

364 **Acknowledgements**: The authors would like to express their gratitude to Reinhard Zbinden, Annelies
365 Zinkernagel and the diagnostic laboratory staff of the Institute of Medical Microbiology for their
366 support in accessing the bacterial clinical isolates, in performing MALDI-TOF and disk diffusion
367 assays, whole-genome sequencing, and in accessing anonymized clinical information. We would like
368 to acknowledge special permit by the University of Zurich to conduct research at the university labs
369 during the COVID-19 lockdown period.

370

371

372 **References**

373 [1] Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory Viral Infection-Induced Microbiome
374 Alterations and Secondary Bacterial Pneumonia. Front Immunol 2018;9:2640.
375 https://doi.org/10.3389/fimmu.2018.02640.
376 [2] Morens DM, Taubenberger JK, Fauci AS. Predominant Role of Bacterial Pneumonia as a Cause of
377 Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness 2009:16.
378 [3] Vincent J-L, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and
379 Outcomes of Infection Among Patients in Intensive Care Units in 2017. JAMA 2020;323:1478–87.
380 https://doi.org/10.1001/jama.2020.2717.
381 [4] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult
382 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet
383 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
384 [5] Du R-H, Liang L-R, Yang C-Q, Wang W, Cao T-Z, Li M, et al. Predictors of mortality for patients with
385 COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J
386 2020;55:2000524. https://doi.org/10.1183/13993003.00524-2020.
387 [6] MacVane SH. Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative
388 Bacterial Infections. J Intensive Care Med 2017;32:25–37.
389 https://doi.org/10.1177/0885066615619895.
390 [7] Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United
391 States. Curr Opin Crit Care 2011;17:472–9. https://doi.org/10.1097/MCC.0b013e32834a4b03.
392 [8] WHO | Tackling antimicrobial resistance in the COVID-19 pandemic. WHO n.d.
393 https://doi.org/10.2471/BLT.20.268573.
394 [9] Rawson TM, Ming D, Ahmad R, Moore LSP, Holmes AH. Antimicrobial use, drug-resistant
395 infections and COVID-19. Nature Reviews Microbiology 2020;18:409–10.
396 https://doi.org/10.1038/s41579-020-0395-y.
397 [10] Rawson TM, Moore LSP, Castro-Sanchez E, Charani E, Davies F, Satta G, et al. COVID-19 and the
398 potential long-term impact on antimicrobial resistance. Journal of Antimicrobial Chemotherapy
399 2020;75:1681–4. https://doi.org/10.1093/jac/dkaa194.
400 [11] Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and
401 fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19
402 antimicrobial prescribing. Clinical Infectious Diseases 2020:ciaa530.
403 https://doi.org/10.1093/cid/ciaa530.
404 [12] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK
405 patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol:
406 prospective observational cohort study. BMJ 2020;369. https://doi.org/10.1136/bmj.m1985.
407 [13] Buehler PK, Zinkernagel AS, Hofmaenner DA, Wendel Garcia PD, Acevedo CT, Gomez-Mejia A, et
408 al. Bacterial pulmonary superinfections are associated with unfavourable outcomes in critically ill
409 COVID-19 patients. Infectious Diseases (except HIV/AIDS); 2020.
410 https://doi.org/10.1101/2020.09.10.20191882.
411 [14] Haigh J, Degun A, Eydmann M, Millar M, Wilks M. Improved Performance of Bacterium and Yeast
412 Identification by a Commercial Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass
413 Spectrometry System in the Clinical Microbiology Laboratory. J Clin Microbiol 2011;49:3441–
414 3441. https://doi.org/10.1128/JCM.00576-11.
415 [15] EUCAST Disk Diffusion Method for Antimicrobial Susceptibility Testing. Version 8.0 (January 2020).
416 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/2020_
417 manuals/Manual_v_8.0_EUCAST_Disk_Test_2020.pdf
418 [16] The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for
419 interpretation of MICs and zone diameters. Version 10.0, 2020.
420 https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Br
421 eakpoint_Tables.pdf

[17] The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_9.0_Breakpoint_Tables.pdf

[18] CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical Laboratory Standards Institute; 2020. n.d.

[19] CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Ninth Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute; 2012. n.d.

[20] Juhas M, Widlake E, Teo J, Huseby DL, Tyrrell JM, Polikanov YS, et al. *In vitro* activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and *Acinetobacter baumannii*. Journal of Antimicrobial Chemotherapy 2019;74:944–52. https://doi.org/10.1093/jac/dky546.

[21] Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data n.d.:7.

[22] McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, et al. The Comprehensive Antibiotic Resistance Database. Antimicrob Agents Chemother 2013;57:3348–57. https://doi.org/10.1128/AAC.00419-13.

[23] Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Research 2019:gkz935. https://doi.org/10.1093/nar/gkz935.

[24] Li X-Z, Plésiat P, Nikaido H. The Challenge of Efflux-Mediated Antibiotic Resistance in Gram-Negative Bacteria. Clin Microbiol Rev 2015;28:337–418. https://doi.org/10.1128/CMR.00117-14.

[25] Jones RN. Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. CLIN INFECT DIS 2010;51:S81–7. https://doi.org/10.1086/653053.

[26] Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res 2020;285:198005. https://doi.org/10.1016/j.virusres.2020.198005.

[27] Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection 2020;0. https://doi.org/10.1016/j.cmi.2020.07.041.

[28] Li J, Wang J, Yang Y, Cai P, Cao J, Cai X, et al. Etiology and antimicrobial resistance of secondary bacterial infections in patients hospitalized with COVID-19 in Wuhan, China: a retrospective analysis. Antimicrob Resist Infect Control 2020;9:153. https://doi.org/10.1186/s13756-020-00819-1.

[29] Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resistance Updates 2016;28:82–90. https://doi.org/10.1016/j.drup.2016.07.003.

[30] Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013;19:216–28. https://doi.org/10.1097/MCP.0b013e32835f27be.

[31] Bhagirath AY, Li Y, Somayajula D, Dadashi M, Badr S, Duan K. Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulm Med 2016;16:174. https://doi.org/10.1186/s12890-016-0339-5.

[32] Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. Clin Microbiol Reviews 2019;32:e00031-19, /cmr/32/4/CMR.00031-19.atom. https://doi.org/10.1128/CMR.00031-19.

[33] Girlich D, Naas T, Nordmann P. Biochemical Characterization of the Naturally Occurring Oxacillinase OXA-50 of Pseudomonas aeruginosa. AAC 2004;48:2043–8. https://doi.org/10.1128/AAC.48.6.2043-2048.2004.

[34] Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, et al. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother 2015;59:6248–55. https://doi.org/10.1128/AAC.00825-15.

[35] Pan Y, Xu Y, Wang Z, Fang Y, Shen J. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa. Arch Microbiol 2016;198:565–71. https://doi.org/10.1007/s00203-016-1215-7.

[36] López-Causapé C, Cabot G, del Barrio-Tofiño E, Oliver A. The Versatile Mutational Resistome of Pseudomonas aeruginosa. Front Microbiol 2018;9:685. https://doi.org/10.3389/fmicb.2018.00685.

[37] Goldstein I, Wallet F, Robert J, Becquemin M-H, Marquette C-H, Rouby J-J. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002;165:171–5. https://doi.org/10.1164/ajrccm.165.2.2107025.

[38] Ioannidou E, Siempos II, Falagas ME. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007;60:1216–26. https://doi.org/10.1093/jac/dkm385.

[39] Becker K, Aranzana-Climent V, Cao S, Nilsson A, Shariatgorji R, Haldimann K, et al. Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice. Clinical Microbiology and Infection 2020. https://doi.org/10.1016/j.cmi.2020.12.004.

[40] Smith KP, Kirby JE. Evaluation of apramycin activity against carbapenem-resistant and -susceptible strains of Enterobacteriaceae. Diagn Microbiol Infect Dis 2016;86:439–41. https://doi.org/10.1016/j.diagmicrobio.2016.09.002.

[41] Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE. In vitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease 2017;88:188–91. https://doi.org/10.1016/j.diagmicrobio.2017.03.006.

Web reference

https://www.fda.gov/drugs/development-resources/plazomicin-injection, date last accessed 12/16/2020